MGMT and glioma: CDC42 showed distinct expression levels in glioma about their clinicopathological characteristics, such as IDH mutation status, MGMT promoter methylation status, 1p/19q codeletion status, pathological classification, and the WHO grade, which were analyzed in the TCGA database (Figure 3A) and validated in the CGGA database (Figure 3B).